192 related articles for article (PubMed ID: 37410676)
21. Red laser-mediated alterations in seed germination, growth, pigments and withanolide content of Ashwagandha [Withania somnifera (L.) Dunal].
Thorat SA; Poojari P; Kaniyassery A; Kiran KR; Satyamoorthy K; Mahato KK; Muthusamy A
J Photochem Photobiol B; 2021 Mar; 216():112144. PubMed ID: 33556702
[TBL] [Abstract][Full Text] [Related]
22. Hypoglycemic activity of withanolides and elicitated Withania somnifera.
Gorelick J; Rosenberg R; Smotrich A; Hanuš L; Bernstein N
Phytochemistry; 2015 Aug; 116():283-289. PubMed ID: 25796090
[TBL] [Abstract][Full Text] [Related]
23. Metabolomics of Withania somnifera (L.) Dunal: Advances and applications.
Tetali SD; Acharya S; Ankari AB; Nanakram V; Raghavendra AS
J Ethnopharmacol; 2021 Mar; 267():113469. PubMed ID: 33075439
[TBL] [Abstract][Full Text] [Related]
24. Withanolides from Withania somnifera Dunal: development of cellular technology and their production.
Sangwan NS; Sabir F; Mishra S; Bansal S; Sangwan RS
Recent Pat Biotechnol; 2014; 8(1):25-35. PubMed ID: 24354530
[TBL] [Abstract][Full Text] [Related]
25. Biodiversity, Biochemical Profiling, and Pharmaco-Commercial Applications of
Gaurav H; Yadav D; Maurya A; Yadav H; Yadav R; Shukla AC; Sharma M; Gupta VK; Palazon J
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770874
[No Abstract] [Full Text] [Related]
26. Withania somnifera (L.) Dunal: Phytochemistry, structure-activity relationship, and anticancer potential.
Tewari D; Chander V; Dhyani A; Sahu S; Gupta P; Patni P; Kalick LS; Bishayee A
Phytomedicine; 2022 Apr; 98():153949. PubMed ID: 35151215
[TBL] [Abstract][Full Text] [Related]
27.
Dutta R; Khalil R; Green R; Mohapatra SS; Mohapatra S
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31731424
[TBL] [Abstract][Full Text] [Related]
28. Withanolide biosynthesis recruits both mevalonate and DOXP pathways of isoprenogenesis in Ashwagandha Withania somnifera L. (Dunal).
Chaurasiya ND; Sangwan NS; Sabir F; Misra L; Sangwan RS
Plant Cell Rep; 2012 Oct; 31(10):1889-97. PubMed ID: 22733207
[TBL] [Abstract][Full Text] [Related]
29. Metabolite Profiling in Withania somnifera Roots Hydroalcoholic Extract Using LC/MS, GC/MS and NMR Spectroscopy.
Trivedi MK; Panda P; Sethi KK; Jana S
Chem Biodivers; 2017 Mar; 14(3):. PubMed ID: 27743505
[TBL] [Abstract][Full Text] [Related]
30. Withania somnifera root extract inhibits MGO-induced skin fibroblast cells dysfunction via ECM-integrin interaction.
Liu X; Chen C; Lin Y; Liu Y; Cai S; Li D; Li L; Xiao P; Yi F
J Ethnopharmacol; 2024 Apr; 323():117699. PubMed ID: 38185262
[TBL] [Abstract][Full Text] [Related]
31. Ashwagandha- Withania somnifera (L.) Dunal as a multipotent neuroprotective remedy for genetically induced motor dysfunction and cellular toxicity in human neurodegenerative disease models of Drosophila.
Murthy MN; Shyamala BV
J Ethnopharmacol; 2024 Jan; 318(Pt A):116897. PubMed ID: 37442493
[TBL] [Abstract][Full Text] [Related]
32. Effect of Ashwagandha Withanolides on Muscle Cell Differentiation.
Wang J; Zhang H; Kaul A; Li K; Priyandoko D; Kaul SC; Wadhwa R
Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680087
[No Abstract] [Full Text] [Related]
33. Neurodegenerative diseases and Withania somnifera (L.): An update.
Dar NJ; MuzamilAhmad
J Ethnopharmacol; 2020 Jun; 256():112769. PubMed ID: 32240781
[TBL] [Abstract][Full Text] [Related]
34. Enhanced withanolide production by overexpression of squalene synthase in Withania somnifera.
Grover A; Samuel G; Bisaria VS; Sundar D
J Biosci Bioeng; 2013 Jun; 115(6):680-5. PubMed ID: 23313565
[TBL] [Abstract][Full Text] [Related]
35. Phyto-therapeutic potential of Withania somnifera: Molecular mechanism and health implications.
Yadav N; Tripathi S; Sangwan NS
Phytother Res; 2024 Mar; 38(3):1695-1714. PubMed ID: 38318763
[TBL] [Abstract][Full Text] [Related]
36. Novel Methods to Generate Active Ingredients-Enriched Ashwagandha Leaves and Extracts.
Kaul SC; Ishida Y; Tamura K; Wada T; Iitsuka T; Garg S; Kim M; Gao R; Nakai S; Okamoto Y; Terao K; Wadhwa R
PLoS One; 2016; 11(12):e0166945. PubMed ID: 27936030
[TBL] [Abstract][Full Text] [Related]
37.
Bhat JA; Akther T; Najar RA; Rasool F; Hamid A
Front Pharmacol; 2022; 13():1029123. PubMed ID: 36578541
[TBL] [Abstract][Full Text] [Related]
38. Withania somnifera (L.) Dunal (Ashwagandha): A comprehensive review on ethnopharmacology, pharmacotherapeutics, biomedicinal and toxicological aspects.
Paul S; Chakraborty S; Anand U; Dey S; Nandy S; Ghorai M; Saha SC; Patil MT; Kandimalla R; Proćków J; Dey A
Biomed Pharmacother; 2021 Nov; 143():112175. PubMed ID: 34649336
[TBL] [Abstract][Full Text] [Related]
39. Light and auxin responsive cytochrome P450s from Withania somnifera Dunal: cloning, expression and molecular modelling of two pairs of homologue genes with differential regulation.
Srivastava S; Sangwan RS; Tripathi S; Mishra B; Narnoliya LK; Misra LN; Sangwan NS
Protoplasma; 2015 Nov; 252(6):1421-37. PubMed ID: 25687294
[TBL] [Abstract][Full Text] [Related]
40. Withaferin A induces Nrf2-dependent protection against liver injury: Role of Keap1-independent mechanisms.
Palliyaguru DL; Chartoumpekis DV; Wakabayashi N; Skoko JJ; Yagishita Y; Singh SV; Kensler TW
Free Radic Biol Med; 2016 Dec; 101():116-128. PubMed ID: 27717869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
